The safety and efficacy of low molecular weight heparin in advanced chronic kidney disease patients diagnosed with NSTE-ACS. Low molecular weight heparin, unfractionated heparin, acute coronary syndrome and advanced chronic kidney disease
Conditions
Interventions
The participants diagnosed with NSTE-ACS were treated with LMWH subcutaneously once daily for at least 2 days.,The participants diagnosed with NSTE-ACS were treated with UFH intravenously for at least
Treatment,Treatment
Low molecular weight heparin (LMWH) group,Unfractionated (UFH) heparin group
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old 2. Diagnosed with NSTE-ACS 3. Advanced chronic kidney disease (CKD stage V) or kidney replacement therapy
Exclusion criteria
Exclusion criteria: 1. Incomplete data 2. Body weight > 150 kg 3. Treated with fibrinolytic agent or fibrin specific agent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major Bleeding complications every day for 7 days Life-thretening bleeding, bleeding required red-cell transfusion at least 2 units or more, hematocrit reduction at least 3 g per dL or more | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrent chest pain or required urgent percutaneous coronary intervention every day for 7 days Self-report chest pain | — |
Countries
Thailand
Contacts
Public ContactWatthikorn Pichitporn
Department of Medicine, Maharat Nakhon Ratchasima Hospital
Outcome results
None listed